NCT00490698View on ClinicalTrials.gov

Zoledronate With Atorvastatin in Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Kidney CancerRenal Cell Carcinoma

Interventions

DRUG

Zoledronate

4 mg IV Once Every 4 Weeks

DRUG

Atorvastatin

20 mg PO Daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER